those we love don't go away they walk beside us every moment
TRANSCRIPT
1
Prof. Ola Nabih Abdel FatahAssistant Professor of Clinical Oncology Assiut University1974 - 2020
Prof. Ola Nabih, a rising star in the oncology field, served as an Assistant professor in the Department of Clinical Oncology at Assiut University and the General Secretary of the Clinical Oncology Department annual conference for 11 consecutive years.
Dr. Ola was a faithful friend and a great physician. Time will not erase her work and the lives she has positively affected. We will be forever grateful for her tremendous efforts and time.
In her memory, we would like to announce the annual Prof. Ola Nabih's Award, Supported by the Assiut Clinical Oncology Department, for the best young oncologist oral poster presenter.
Those we love don't go away ... They walk beside us every moment
Welcome MessageDear Colleagues and Friends, It is a great pleasure and honor to extend you a warm invitation to attend the 12th Annual international conference of clinical oncology department, Assuit university, That will be held on February 24- 26, 2021 in Jolie Ville Hotel, Luxor, EgyptThis conference will be done in collaboration with Arab Medical Association Against Cancer(AMAAC), Egyptian Cancer Society (ECS), Kasr EL-Aini School of Oncology (KASO), EgyptianHematology Oncology Group (EHOG) and, the Egyptian Society for Liver Cancer (ESLC).Our goal is to bring together national and International expert oncologists to improve the knowledge about the new trends and challenges in management of various cancers and to build an international scientific collaborative network.We welcome your participation in this educational program and we hope you will enjoy the conference and the beautiful culture and architectures of Luxor
Prof. Samir Shehata Mohamed
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
2
Conference Moderators
Head of Organizing Committee
Head of Scientific Committee
Honorary PresidentsProf. Sami ElKhatib
President of AMAAC
Prof. Hussien KhaledPresident of EHOG
Prof. Hamdy Abdel AzimPresident of KASO
Prof. Mostafa ElSerafiPresident of Egyptian Cancer Society
Prof. Ashraf OmarPresident of ESLC
Prof. Amina Mohamed MostafaProf. of Clinical Oncology
Prof. Samia Abdel KareemProf. of Clinical Oncology
Prof. Mohamed MekkawyProf. of Clinical Oncology
Prof. Hatem Abo ElkassemDean of NCI
Under the Patronage of
Prof. Shehata GhareebVice President for Education
Student Affairs
Prof. Maha Kamel GhanemVice President for EnvironmentalAffairs and Community Service
Prof. Tarek El GammalPresident of Assuit University
Prof. Ahmed El MenshawyVice President for Graduate
Studies and Research
Conference President Prof. Samir Shehata Mohamed
Head of Clinical Oncology and Nuclear Medicine Department
Prof. Maha SalahAss. Prof. of Clinical Oncology
Prof. Reham Abdel-WahabAss. Prof. of Clinical Oncology
Prof. Hanan Gamal Eldin Prof. of Clinical Oncology
Prof. Hoda Hassan EssaProf. of Clinical Oncology
Prof. Taha ZakiProf. of Clinical Oncology
Prof. Samy El-GezawyProf. of Clinical Oncology
Dean of Faculty of MedicineProf. Alaa Attia
3
Members of Scientific Committee
Members of Organizing Committee:
Abbas OmarAbdel Aziz BelalAbdel Salam AttiaAbeer FayekAdel ElSayesAhmed AllamAhmed AlshehryAhmed ElDorryAhmed ElZawawyAhmed GamalAhmed Saad EldinAlaa ElhaddadAlaa KandilAly Shams EldinAmal EmamAmal RyanAmany SaberAmen Hamdy ZakiAmeny HelalAshraf BarakatAshraf ElghandourAshraf FarragAsmaa Abdel TawabAyat MorsyAyman Abdel SameeaDalia Abd ElmoetyDoaa Aly GamalEhab KhalilEhab MostafaEhsan ElghoniemyEmad DawoudEmad EhabEmad HamadaFady GearaFouad Abo TalebGamal ElHosienyHamdy Abdel AzimHamdy ElzawamHamed Mostafa
Hanaa KohilHanan HamedHasham Abdel ElSemeeaHassan GaafarHala elshenshawyHatem AmeenHazem ElakadHeba ElzawahryHesham ElGhazalyHesham ElwakilHesham HamzaHesham MostafaHesham TawfeekHoda Abdel BakyHoda HassanHosna MostafaHossam KamelHussin RabieeIbrahim AlSheneberIbrahim AwadIbtesam Saad EldeenInas Abdel HalimKamal ElghamrawyKhaled Abdel KareemKhaled KamalLaila MoussaLamia MahmoudLobna Ezz ElarabLobna SedkyMagda AllamMagda MostafaMagdy SaberMaha ElZafaranyMahmoud EltohamyMahmoud EmetienyMahmoud SalahManal ElSouradyManal MoawadMarwa Ismail
Marwan GhosnMedhat ElsebaieMervat ElNaggarMervat MattarMervat OmerMohamed AbdallahMohamed Abdel HakimMohamed Abdel KaderMohamed Abdel MoatyMohamed Aboel FotouhMohamed AlaaMohamed AlbassuniMohamed AzazziMohamed ElsherbenyMohamed FaroukMohamed Hosam KhaledMohamed KhalafMohamed LotayefMohamed MostafaMohamed MoussaMohamed Saad ZaghloulMohamed SalahMohamed SolimanMohammed HosnyMohsen BarsoomMohsen MokhtarMona Abo El AninMonier Abo ElelaMostafa Abdel WanisMostafa ElSharkawyNabil MobarakNadia Abdel MonemNadia ElDeebNadia MahhanyNagi ElSaghirNaser Abdel BaryNasr EllahloubiNeemat KassemNier ElGhamry
Noha AdlyOla KhorshidOm Elkhair Abo ElkairOmar FahmyOmar ZakiOsama ElmaltOthman MansourRabab GhafaarRafaat Abdel FattahRehab FaroukSaied NewaemSalah Abdel MoniemSalah El MesedySamar ElmorshedySameh ShamaaSamy ErfanSamy ElbadawySayed MostafaSeham ElhagrasyShawky BaserbashyShawky ElHadadSherif AbdelwahabSoher lsmailSomia EzzatTamer RefaatTarek ElgoharyTarek HashemTarek SalahTarek ShowmanWafaa ElmetnawyWafaa MohamedWalid ElNahhasWalid DiabYasser Abdel GawadYasser Abdel KaderYasser KhafagaYosra DorghamYosri RostumYosri Wassef
Ereny SamuelAhmed AshrafDina Barakat
Nada HasanHeba Bakri Heba Sheha
Mariam MohsenDoaa Abd El-AleemYousra FarghalyDonia Hussien
Ahmed GamalSohiala EsamRehab OsamaGehad ahmed
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
4
Registration
GIT (I) Session
15:00- 15:30 Recent advances in management of GEJ locally advanced and metastatic setting
Prof. Salem Eid Prof. Mohamed Farouk 15:30- 15:50 Advanced biliary cancer : How to deal ? (Virtual)
Prof. Shawki Bazarbashi (KSA)
15:50- 16:10 Surgical management of pancreatic cancer Prof. Ibrahim Al Sheneber (KSA) (Virtual)
16:10- 16:30 Immunotherapy in HCC Prof. Amr Shafik (Virtual)
16:30- 16:50 Total neoadjuvant strategies for colon and rectal cancer: what’s new in oncology.
Prof. Ahmed Seleem
16:50- 17:00 Round Table Discussion GIT (1)
24th
FEBRUARY
WEDNESDAY
24th
FEBRUARY
WEDNESDAY
12:0015:00
15:0017:00
Hall (A)
Chairpersons (Alphabetically):
Prof. Abdelaziz BelalProf. Abdelsalam Attia Prof. Amany SaberProf. Ashraf Barakat
Prof. Emad Shash Prof. Hesham TawfikProf. Inas AbdelhalimProf. Mohamed Abo ElFotouh
ModeratorsProf. Abbas OmarProf. Hesham Elghazaly
5
Management of first line mCRC
24th
FEBRUARY
WEDNESDAY
17:0017:30
Chairperson : Prof. Emad HamadaSpeaker: Prof. Mohamed Abdallah
Hall (A)
(Amgen Symposim)
Trifluridine/Tipiracil; Fingerprint in GI oncology
24th
FEBRUARY
WEDNESDAY
17:3018:00
Chairperson : Prof. Samir ShehataSpeaker: Prof. Mohamed Abdallah
Hall (A)
(Servier Symposim)
GIT (II) Session
24th
FEBRUARY
WEDNESDAY
18:0019:20
Hall (A)
18:00- 18:20 Adjuvant treatment in CRC (Virtual) Prof. Sahin Lacin (USA)
18:20- 18:40 Met. CRC with limited liver mets (Virtual) Prof . Alexandra Stewart (UK)
18:40- 19:10 Personalized approach in m. CRC Prof. Mohamed Abdallah
19:10-19:20 Round Table Discussion (GIT II)
Chairpersons (Alphabetically):
Prof. Hussien Fakhry Prof. Hussein MekkyProf. Mohamed Basiouny Prof. Mohamed GamilProf. Mostafa Abdel Wanis
Prof. Nadia Abdel MoniemProf. Samy RamzyProf. Seham ELhagrasy Prof. Wafaa Elmitnawy
ModeratorsProf. Magda AllamProf. Nehal El-MashadProf. Yosry Rostom
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
6
GIST A real precision drived tumor
24th
FEBRUARY
WEDNESDAY
19:2019:50
Speaker: Prof. Mohsen Mokhtar
Hall (A)
(Bayer Symposium)
Treatment sequence optimization for mCRC patients + Case Discussion 24th
FEBRUARY
WEDNESDAY
19:50 20:20
Speaker: Prof. Tarek HashemCase Discussion : Prof. Hossam Elashtokhy
Hall (A)
(Merck Symposium)
Enhancing Patients’ Choices with Biosimilars
24th
FEBRUARY
WEDNESDAY
20:20 20.50
Speaker: Prof. Mohsen Mokhtar
Hall (A)
(Sandoz Symposium)
7
GU Session
15:00- 15:20 Chemotherapy, immunotherapy or combinations: What is the best option in the face of new evidence in advanced UB ? Prof. Ahmed Saadeddin (KSA) (Virtual)
15:20- 15:40 The Future Is Now?: Targeted Therapy in Endometrial Cancer Prof. Hassan Gaffar (UAE) (Virtual)
15:40- 16:00 Sentinel lymph node in endometrial cancer
Prof. Gamal Emera
16:00- 16:20 Surgery in cancer patients in the era of covid 19 Prof. Hesham Abu Taleb
16:20- 16:40 Overview of Immunotherapeutic Approaches in Ovarian Cancer Prof. Rami Ghali (Virtual)
16:40- 17:00 First-Line PARP inhibition in ovarian cancer : The success storyProf. Sami El Gizawy
17:00- 17:20 How to sequence ttt in M. RCCProf. Emad Hamada
24th
FEBRUARY
WEDNESDAY
15:0019:00
Hall (B)
Chairpersons (Alphabetically):
Prof. Hazem ElAKaadProf. Khaled KamalProf. Osama ElMaltProf. Osman Mansour
Prof. Rasha Hagag Prof. Saied Noeiam Prof. Tarek Hashem Prof. Wafaa Ashour
ModeratorsProf. Ibtesam Saad EldinProf. Taha Zaki
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
8
Round Table Discussion (GU)24th
FEBRUARY
WEDNESDAY
18:4019:00
Hall (B)
A new Paradigm in management of mHSPC patients 24th
FEBRUARY
WEDNESDAY
18:1018:40
(Janssen Symposium)
Hall (B)
Speaker: Prof. Mohamed Abdallah
State of Art in Management of Metastatic Prostate Cancer 24th
FEBRUARY
WEDNESDAY
17:5018:10
Chairperson : Prof. Samir ShehataSpeaker: Prof. Emad Hamada
(Sanofi Symposium)
Hall (B)
Role of Fulvestrant in endocrine receptors +ve breast cancer patients 24th
FEBRUARY
WEDNESDAY
19:3020:00
Speaker: Prof. Hassan Metwally
(Sandoz Symposium)
Hall (B)
Chemotherapy Optimal Management of HER2 Negative MBC 24th
FEBRUARY
WEDNESDAY
19:00 19:30
Speaker: Prof. Hamdy Abdel Azim
(New Bridge Symposium)
Hall (B)
Personalized approach in the management of CRPC patients 24th
FEBRUARY
WEDNESDAY
17:2017:50
Moderator : Prof. Hesham TawfikSpeaker: Prof. Salem Eid
(Astellas Symposium)
Hall (B)
9
25th
FEBRUARY
THURSDAY
Breast (I) Session
10:00- 11:30 Challenging the standards in ttt of EBC : • CDk4/6 inhibitors in Adjuvant setting • Immunotherapy therapy in neoadjuvant NATNBC • Response driven ttt of HER2 +ve EBC
13:00- 13:20 ABC guidelines , background and updates in metastatic breast cancer Prof. Nagi Elsaghir (Lebanon) (Virtual)
13:20- 13:50 Breast cancer in young women from biology to treatment and survivorship. Prof. Matteo Lambertini (Italy) (Virtual)
13:50- 14:00 Round table discussion breast 1
10:00 14:00
Hall (A)
Chairpersons (Alphabetically):
Prof. Ashraf SelimProf. Elia AnisProf. Emad Khallaf
Prof. Samir ShehataProf. Sherif NaguibDr. Loay Kassem
Moderator & SpeakerProf. Hamdy Abdel Azim
25th
FEBRUARY
THURSDAY
Hall (A)
Treatment optimization of HER2+ eBC: The Science and Art
11:3013:00
Panelists (Alphabetically):Prof. Ahmed Abd ElazizProf. Alaa Kandil
Prof. Ashraf SelimProf. Dorria Salem
Prof. Omar ZakaryaProf. Sherif NaguibDr Loay Kassem
Roche Symposium
Speaker: Prof. Hamdy Abdel Azim
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
10
14:00- 14:20 Novel therapies for refractory and relapsed HER2 + ve MBCProf. Marwan Ghosn (Virtual)
14:20- 14:40 What is beyond CD4/6 inhibitors in HR+ve Her2-ve breast cancer Prof. Alaa Kandil
14:40- 15:00 Optimal use of PARPI to improve breast outcomesProf. Marwa Ismail
15:00- 16:00 Lunch Break16:00- 16:20 Immunotherapy in m .TNBC
Prof. Nasr Allahloubi
25th
FEBRUARY
THURSDAY
Session Breast (II)14:00 16:00
Hall (A)
Chairpersons (Alphabetically):
Prof. Ahmed HassanProf. Hassan Metwally Prof. Hesham HamzaProf. Lobna Sedky
Prof. Mohamed HassProf. Nabil MubarkProf. Tarek ShomanProf. Yasser El KarmProf. Yousry Wassef
ModeratorsProf. Sherif Abdel WahabProf. Waleed Arafat
25th
FEBRUARY
THURSDAY
Hall (A)
Biosimilars in Breast Cancer16:20 16:50
Chairperson : Prof. Emad HamadaSpeaker: Prof. Hamdy Abdel Azim
(Amgen Symposium)
25th
FEBRUARY
THURSDAY
Hall (A)
Oral chemotherapy in times of Covid-1916:50 17:20
Speaker: Prof. Emad Hamada
(Pierre Fabre Symposium)
11
25th
FEBRUARY
THURSDAY
Lung Session
17:20- 17:40 Adjuvant treatment for EGFR positive NSCLCProf. Mahmoud Abdelsalam (Canada) (Virtual)
17:40- 18:00 Emerging strategies in EGFR mutant metastatic NSCLC treatment Prof. Yasser Abdelkader
18:00- 18:20 ALK inhibitors sequencing in lung cancerProf. Rabab Gaafar
18:20- 18:40 SCLC in the era of immunotherapy .Prof. Ahmed Magdi
18:40- 19:00 Mesothelioma updated management Prof. Nafisa Abd ElHafiz (KSA) (Virtual)
19:00- 19:15 Round Table Discussion lung
17:20 19:15
Hall (A)
Chairpersons (Alphabetically):
Prof. Amany HelalProf. Hala EL ShenshawyProf. Hanaa Kohil
Prof. Mohamed Abd ElkaderProf. Mohamed MekkawyProf. Nasr Abd El BaryProf. Olaa Khorshid
ModeratorsProf. Lobna Ezz ElArabProf. Maha Kamel Ghanem Prof. Samir Shehata
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
12
ChairpersonsProf.Hesham Tawfik Prof. Tarek Hashem
ChairpersonsProf. Hesham Tawfik Prof. Tarek Hashem
25th
FEBRUARY
THURSDAY
25th
FEBRUARY
THURSDAY
Hall (A)
Hall (A)
5 Years Survival for Young women
From theory to practice: case presentation
19:1519:35
19:3519:55
(Novartis Symposium)
(Novartis Symposium)
Speaker: Prof.Heba El Zawahry
Speaker:Dr. Nawal El Tohamy
25th
FEBRUARY
THURSDAY
Opening ceremony20:0021:00
Hall (A)
13Break 12:00-12:15
25th
FEBRUARY
THURSDAY
Hematology session10:0015:00
Hall (B)
Chairpersons and panelistsProf. Adel Abdel RehimProf. Mahmoud Salah Prof. Mohamed Abdel Moaty
Prof. Mohamed MoussaProf. Osama HassanProf. Sameh Shamaa
25th
FEBRUARY
THURSDAY
25th
FEBRUARY
THURSDAY
25th
FEBRUARY
THURSDAY
25th
FEBRUARY
THURSDAY
The Role of immunotherapy in the fourth line treatment of cHL
Multiple myeloma from Clinical trials to Real-World evidence
Relapsed /Refractory Multiple Myeloma
Round Table Discussion (MM)
10:0010:30
10:3011:00
11:0011:30
11:3012:00
Hall (B)
Hall (B)
Hall (B)
Hall (B)
(MSD Symposium)
(Takeda Symposium)
(Amgen Symposium)
Speaker: Prof. Rafaat Abdel Fattah
Speaker: Prof. Mohamed Moussa
Speaker: Prof. Mohamed Abdel Moaty
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
14
25th
FEBRUARY
THURSDAY
Better future for Lymphoma Patients : Mabthera SC in Action
14:3015:00
25th
FEBRUARY
THURSDAY
Round Table Discussion (CLL)13:1514:30
Hall (B)
Hall (B)
25th
FEBRUARY
THURSDAY
Redefining Expectations in AML12:1512:30
Hall (B)
(Abbvie Symposium)Speaker: Prof. Gamal Fathy
25th
FEBRUARY
THURSDAY
Moving to a new era in CLL12:3012:45
Hall (B)
(Abbvie Symposium)Speaker: Prof. Mervat Mattar
25th
FEBRUARY
THURSDAY
Update in frontline therapy in CLL12:4513:15
Hall (B)
(Janssen Symposium)
(Roche Symposium)
Speaker: Prof. Rafaat Abdel Fattah
Lunch break 15:00-16:00
25th
FEBRUARY
THURSDAY
Hematology session
Hall (B)
Chairpersons and panelistsProf. Gamal Fathy Prof. George Bahig
Prof. Mervat MattarProf. Mohamed Azazi
Prof. Mohamed KhalafProf. Sherief Mahmoud
Speaker: Prof. Mohamed Abdel Moaty
15
25th
FEBRUARY
THURSDAY
Head and Neck Session16:0017:30
Hall (B)
16:00- 16:20 Prevention and screening in H&N cancer Prof. Abhishek Shankar (India) (Virtual)
16:20- 16:40 Coupling and decoupling of tumer immunity from auto immunity induced by check point inhibi-tors .
Prof . Adi Diab (USA) (Virtual)
16:40- 17:00 Recent updates in Immune therapy in H&NProf. Mohsen Mokhtar
17:00- 17:20 Gamma Knife radiosurgery for pituitary adenomaProf. Khaled Abdel Karim
17:20- 17:30 Round table discussion H&N
Chairpersons (Alphabetically):
Prof. Hesham MostafaProf. Medhat ElSebaieProf. Mervat ElNagarProf. Mostafa Hashem
Prof. Rafaat Aly Saber Prof. Sayed Mostafa Prof. Yosry Goda
ModeratorsProf. Hoda Abdel BakyProf. Maha ElNagar
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
16
25th
FEBRUARY
THURSDAY
Evolving role of PI3k inhibitors in management of HR+ve HER2-ve ABC
19:00 19:20
Hall (B)
25th
FEBRUARY
THURSDAY
Changing land scape of 1st line NSCLC management
18:0018:30
Hall (B)
(BMS Symposium)
(Novartis Symposium)
25th
FEBRUARY
THURSDAY
Paradigm shift of 1st line treatment in HNSCC
17:3018:00
Hall (B)
(MSD Symposium)
Speaker: Prof .Mohamed Abdallah
Speaker: Prof. Hamdy Abdel Azim
25th
FEBRUARY
THURSDAY
Ibrance: Translating evidence to real world practice
18:30 19:00
Hall (B)
(Pfizer Symposium)
Speaker: Prof. Alaa Kandil
Chairpersons : Prof.Yasser Abdel Kadder Speaker: Prof. Alaa Kandil
17
25th
FEBRUARY
THURSDAY
Opening ceremony20:0021:00
Hall (A)
Counselor. Mostafa Alham
Prof. Tarek El Gammal
Prof. Ahmed El Menshawy
Prof. Shehata Ghareeb
Prof. Maha Kamel Ghanem
Prof. Alaa Attia
Prof. Hatem Abo ElKassem
Prof Youssef Salah
Prof Amany Omar
Prof Saad Zaki
Prof. Sami ElKhatib
Prof. Hussien Khaled
Prof. Hamdy Abdel Azim
Prof. Mostafa ElSerafy
Prof. Ashraf Omar
Prof. Samir Shehata
Luxor Governor
President of Assuit University
Vice President for Graduate Studies and Research
Vice President for Education Student Affairs
Vice President for Environmental Affairs and Commu-nity Service
Dean of Faculty of Medicine, Assuit university
Dean of NCI
Vice Dean of the College of Graduate Studies
Vice Dean of Education student affairs
Vice Dean of Environmental Affairs and Community Service
President of AMAAC
President of EHOG
President of KASO
President of Egyptian Cancer Society
President of ESLC
President of the Conference
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
18
(Best oral presentation) Session10:00 12:00
Hall (A)
26th
FEBRUARY
FRIDAY
Chairpersons (Alphabetically):
Prof. Abdel Motlib Mohamed Prof. Ahmed Elzawawy Prof. Hosna MostafaProf. Kamal ElghamrawyProf. Mostafa ElserafyProf. Omar Shebl
Prof. Omar ZakiProf. Salah Abdel MoniemProf. Salah ElmesidyProf. Sami ElkhatibProf. Samia abdel KarimProf. Samir Shehata
Moderator Prof. Hussien Khaled
10:00- 10:15 Head & Neck CancerAss. Lecturer :Ahmed Mostafa
10:15- 10:30 Case presentation GU ovarianAss. Lecturer :Nada Hassan
10:30- 10:45 HaematologyAss. Lecturer :Walaa Gamal
10:45- 11:00 Breast Ass. Lecturer :Heba Bakri
11:00- 11:15 BreastAss. Lecturer :Ahmed Hadeya
11:15- 11:30 Round table discussion
19
(Radiotherapy workshop) (Virtual)
13:00 18:15
Hall (A)
26th
FEBRUARY
FRIDAY
Chairpersons (Alphabetically):
Prof. Ahmed El Sayed Prof. Ihab MostafaProf. Mohamed Wahman
Prof. Soha Abd El RazikProf. Somaya Ezzat
ModeratorsProf. Ahmed MarzokProf. Ashraf Farrag Prof. Mostafa El Hadad
13:00- 13:30 Role of radiotherapy in oligometastatic diseaseProf. Michael Eble (Germany)
13:30- 13:45 Flash RTH : A new hope to improve therapeutic ratio Prof. Kamal ElGhamrawy
13:45- 14:15 Cyber Knife : A technology recently serve in Egypt Prof. Mohamed Saad Zaghlol
14:15- 14:45 Radio therapeutic options in management of vulvar carcinomaProf. Mohamed Elsheikh (USA)
14:45- 15:15 MRI guided Rth for upper abdominal tumors advantages and limitationsProf. Tamer Refat (USA)
15:15- 15:45 Challenges and controversies in breast cancer radiation therapyProf. Fady Geara (Lebanon)
15:45- 16:15 Hypo fractionated breast RT :The less, The betterProf. Tarek Salah
16:15- 16:45 Re irradiation in Head and Neck cancerDr. Ahmed Allam
16:45- 17:15 RTH in era of Covid 19 : what is newProf. Belal Elhawary (Jordan)
17:15- 17:45 Recent advances in pediatric imagingProf. Hany Hafez
17:45- 18:15 Round table discussion
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
20
26th
FEBRUARY
FRIDAY
Clinical Pharmacy Work Shop(Virtual)
10:0012:00
Hall (B)
Chairpersons (Alphabetically):
Prof. Ekramy Abd ElRehim Prof. Dina FathallaProf. Mahmoud Shiha
Prof. Mohamed Abd El LatifDr. Ali Al Rumaih
ModeratorProf. Abdallah Abotaleb
10.00-10.20 Pharmacist rules during pandemic eraDr . Fakhr Al Ayoubi
10.20-10.40 Pharmacists and COVID 19 vaccinesProf. Abdallah Abotaleb
10.40-11.00 Pharmacists and resources allocations in oncology fieldMs. Lynn Al Tayara
11.00-11.20 What should pharmacists know about cancer future therapiesProf. Ekramy Abd ElRehim
11.20-11.40 Management of mucositits in H&N cancer patientsClin. Ph. Ahmed El Sarrif
11.40-12.00 Introduction and management of neutropenia Clin. Ph. Toka Safwat Clin. Ph .Marwa Kamal
Round Table Discussion
21
CORRELATION BETWEEN CLINICAL OUTCOMES AND PROLIFERATIVE INDEX (Ki-67) IN PATIENTS
WITH CANCER CERVIX Dungersi SH1, Belal AM1, Hegazy NEE1, Abdallah DM2
1Alexandria Clinical Oncology Department, Faculty of Medicine, Alexandria University, 2Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Introduction
Cervical cancer still poses a major problem in regards to mortality in
developing countries and hence the need to develop novel biomarkers to
predict prognosis and response.
The objectives of this study were to assess the correlation between Ki-67
and clinic-pathologic outcomes as well as to determine the response to
treatment in relation to Ki-67 and TILS. Secondary objectives included to
determine the one year overall survival and progression free survival in
relation to Ki-67.
Patients and Methods
Thirty patients with cervical cancer being treated at the Alexandria
University Main Hospital, Clinical Oncology department were selected.
Clinico-pathologic data was retrieved from the patient files.
Ki-67 and TILS were analyzed from the patient blocks. Chi square test,
Pearson correlation and Kaplan-Meier method was used to study the
associations and correlations between Ki-67, TILS and clinic-pathologic
outcomes, survival and progression free survival.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
22
Results
Important clinical features of the studied group include median age of 51
(range 30-77y), FIGO stage ⅠⅠB, lymph node metastasis (66.7%),
squamous cell carcinoma (80%), adenocarcinoma (10%).
There was no significant association between clinic-pathologic outcomes
including parametrial invasion (P(MC)=0.908), vaginal infiltration
(P(MC)=0.251), lymph node metastasis (P(MC)=0.182), FIGO stage
(P(MC)=0.736), histology (P(MC)=0.269), tumor grade (P(MC)=0.216 ),
tumor size (P=0.353) and Ki-67.
Response to treatment in relation to Ki-67 was statistically not significant
(p=0.924).
TILS and response to treatment did not demonstrate significant association
(p=0.183).
One year overall survival and PFS in relation to Ki-67 was not statistically
significant (p=0.248, p=0.867).
Interestingly a significant low positive correlation was noted between Ki-
67 and TILS (Pearson Correlation=0.378, p=0.039)
Conclusion
Expression of Ki-67 in cervical cancer is of doubtful value in relation to
clinical outcomes.
Both Ki-67 and TILS was limited in predicting tumor response.
There seems to be no relationship between Ki-67 and OS and PFS.
Notably a low positive correlation between Ki-67 and TILS was observed.
23
Abstract:
Microparticles and PD1 Interplay in Multiple Myeloma and Treatment Outcomes, Non Randomized Controlled Study
Asmaa M. Zahran1, Amal Rayan2
1Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
2Clinical Oncology Department, Faculty of medicine, Assiut University, Assiut, Egypt.
Correspondence to: Amal Rayan
E-mail: [email protected]
Postal address: 71515, Assiut university hospital
ORCID iD: 0000-0001-5995-9177
Abstract topic: active multiple myeloma
Abstract structure:
Background:
Although multiple myeloma (MM) is still considered as an incurable disease by current
standards, the development of several combination therapies, and immunotherapy
approaches has raised the hope towards transforming MM into an indolent, chronic
disease, and possibly achieving a cure.
Objectives:
We tried to shed light on the expression of PD1 and different Microparticles (MPs)
in MM and their interplay as a mechanism of resistance to standardized treatments,
in addition, find their associations with prognostic factors of MM.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
24
Methods:
thirty patients with newly diagnosed and chemotherapy naïve active MM, along
with 20 healthy participants of comparable age and sex were recruited, after
diagnosis of MM; blood samples were collected from both patients and controls for
flow cytometric detection of CD4+, CD8+, CD4+PD1+, and CD8+PD1+ T cells,
total MPs, CD138+ MPs, and platelet MPs.
Results:
MM patients had statistically significant higher levels of TMPs, CD138+M compared to
their controls, while PMPs exhibited no significant difference between both groups.
Statistically significant higher percentages of CD8+T cells, PD1+CD8+, PD1+CD4+T cells
were detected in patients compared to controls, while the latter group had a significantly
higher percentage of CD4+T cells than MM patients, patients who didn't achieve complete
response, had significantly higher percentages of PMPs, CD138+MPs, PD1+CD8+,
PD1+CD4+, and CD8+T cells (cutoff values= 61, 10.6, 13.5, 11.3 & 20.1 respectively),
(p-values=0.002, 0.003, 0.017, 0.001 & 0.008 respectively).
Conclusion:
Microparticles and PD1 expressions were associated with proliferative potential and
resistance to Bortezomib-based treatments, our results suggested that they played a crucial
role in myeloma progression.
25
EVALUATION OF CHEMOTHERAPY SERVICE ATTHE
ALEXANDRIA UNIVERSITY CLINICAL ONCOLOGY
DEPARTMENT IN VIEW OF INTERNATIONAL
RECOMMENDATIONS
Regina NO1, Ashraf ME1, Sherif FE1 1Alexandria Clinical Oncology Department, Faculty of Medicine, Alexandria
University, Alexandria Egypt.
Introduction
Chemotherapy plays a major role in the current management of adult
oncology patients. The purpose of this study was to assess the aspects of
chemotherapy service in the clinical oncology department Alexandria
university hospital, to come up with recommendations and a chemotherapy
checklist to facilitate the chemotherapy process.
Patients and methods
This was a prospective observational study conducted on 300 new adult
patients seen from August 2019 to February 2020. Data were collected
from the prescription of the first cycle to the end of the chemotherapy
treatment. The patients’ demographic data, clinical details and
chemotherapy data were collected and analyzed using SPSS version 2.
Results.
The median age was 54 years old with a range of 17-83 years. 71.3% of
the patients were overweight or obese. Breast cancer accounted for 24.3%
of the cases, ovarian (6.7%) and colon/lung cancer (5.7%) each.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
26
Adriamycin/cyclophosphamide then Taxane was the most commonly used
regimen (16.7%), followed by Taxo/Carbo (12.3%) and Gem/cisplatin
(7%). Majority of the patients were on outpatient chemotherapy
(77%) and 23% were inpatients. A small percentage of patients (5%)
received target therapy. 82% of patients were on intravenous
chemotherapy and 6.3% on oral chemotherapy. 100% of the patients gave
verbal consent before the start of treatment. 21% of the patients had dose
modifications during their treatment cycle due to hematological toxicity
(29%), renal impairment (4%) or hepatic impairment (5%). The number of
chemotherapy cycles ranged between 3-8 cycles and the mean treatment
duration was 4 months. 4 out of 300 patients (1.3%) died before
completion of their treatment. 8.3% had neurological toxicity (72.2 %
grade 1&2, 27.8% grade 3) and 29% of patients developed hematological
toxicities (39.6% grade 1&2, 60.4 grade 3&4).5% of the patients had acute
gastrointestinal side effects. There was a statistical significant correlation
between the hematological toxicity and the treatment duration
(3.97 vs. 3.23), (p=0.002). Neurological toxicity also had a
significant correlation with the treatment duration (3.50 vs. 4.37),
(p=0.016). High BMI was correlated with increased incidence
of breast cancer, ovarian cancer, nasopharyngeal cancer,
esophageal cancer, Hepatocellular carcinoma and neuroendocrine
tumors.
Conclusion & recommendations
There is need to enhance support services for patients such as counseling
and nutritional advice. Provision of more targeted therapy is needed.
27
Written documented consent forms should be signed before chemotherapy.
Prompt management of hematological and neurological side effects will
lead to timely completion of the chemotherapy cycles. In addition, given
the current COVID 19 pandemic less intravenous chemotherapy, more oral
prescriptions, less inpatient treatments, use of 3 weekly regimen instead of
weekly and adequate social distancing are mandatory measures to reduce
exposure of our immunocompromised patients during the hospital visits.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
28
PRIMARY PEDIATRIC MALIGNANT BONE TUMORS;
A 10-YEAR OUTCOME.
Noordin BS1, Shady HF1, Bassma ME1, Alaa EK1
Alexandria Clinical oncology Department, Faculty of Medicine, Alexandria University.
INTRODUCTION
Primary pediatric bone tumors are very rare neoplasms and account for
approximately 6% of all childhood cancers. Osteosarcoma and The Ewing
sarcoma family of tumors are the two most common pediatric bone
malignancies accounting for 56% and 34% respectively. Others such as
chondrosarcoma (6%) are rarely seen in skeletally immature patients.
AIM OF THE WORK;
To evaluate treatment out-comes and prognostic factors in patient with
primary pediatric malignancies treated at Alexandria clinical oncology
department, in Alexandria university Hospital and Borg El-Arab university
Hospital in Egypt.
METHODOLOGY; This was a retrospective study, one hundred and fifty-four cases from January 2010 to
2019 December were retrieved from Files, clinical characteristic and treatment
outcomes were recorded.
RESULT Osteosarcoma accounted for majority of the cases 50% (n=77) followed by
Ewing sarcoma 48.7% (n=75) and the least common was chondrosarcoma
29
1.3% (n=2). Both osteosarcoma and Ewing’s sarcoma had a slight male
predominance, 57.1% (n=44) and 61.3% (n=46) respectively. Pain was the
most common presenting symptom in both tumors.
The 5-year overall survival for both localized and metastatic
osteosarcoma was 63.2%. Patient who presented with localized
osteosarcoma had 5-year overall survival of 75.8% while those who
presented metastatic disease had 5-year overall survival of 38.2%, this was
statistically significant with p-value of 0.016. The most common site for
metastasis was lungs, accounting for 65.71% (n=23) of the metastatic sites,
followed by spread to other bones 22.86%(n=8).
Patient with Ewing sarcoma, both with metastatic and non-
metastatic disease had a 5-year overall survival of 61.2%. Those
who presented with localized disease had 5-year overall survival
of 71.7% while those with metastatic disease at presentation had
41.2%, the difference was statistically significant with p-value of
0.022. The most common site for metastasis was also lungs
accounting for 62.5% (n=20) of the metastatic sites.
CONCLUSION: Patients with pediatric bone malignancies treated at Alexandria clinical
oncology department, in Alexandria university Hospital and Borg El Arab
university hospital had similar demographics and treatment outcome as
patients in the developed world.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
30
COMPARISION OF 7TH AND 8TH EDITIONS AJCC/UICC TNM STAGING IN CORRELATION WITH
SURVIVAL AND TREATMENT GUIDELINES FOR NON-SMALL CELL LUNG CANCER.
Irura TW1, Zahra OS2, Sherif FE3, Ahmed B4
1Resident in Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.
2 Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.
3 Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.
4Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine University of Alexandria, Egypt.
BACKGROUND
Worldwide, lung cancer continues to be the leading cause of cancer-related
deaths, despite screening and treatment progress with the lowest 5yr
survival rates, under 20% in developed countries. In Egypt, lung cancer is
the most lethal malignancy. Most patients present with locally advanced or
metastatic disease.
NSCLC comprise of 85-90% of all newly diagnosed lung and bronchus
tumors. The American joint committee on cancer (AJCC)/International
Union for Cancer Control (UICC) Tumor, Node and Metastasis (TNM)
staging system for lung cancer has been revised from the 5th to the 8th
editions over the last two decades.
31
The TNM Staging system can separate survival outcomes between the
stage, it can give the prognosis of the patient and the clinician can decide
the treatment modalities.
This study sought to show the discriminatory ability of this new staging
system and compare it with the 7th in the Egyptian patient cohort.
AIM OF THE WORK
This work aims to:
1. Reviewing all demographic and clinic-pathological features of these patients
2. Evaluate the discriminatory ability of the revised 8th edition T category, M
category and the prognostic accuracy of the staging system and compare it
with the 7th edition staging system.
METHODS
In this retrospective population-based cohort, data on patient characteristics, tumor
characteristics, diagnostic tools used to reach a diagnosis and treatment modalities
administered has been collected from the archive of Alexandria Clinical Oncology
Department.
Then all the patients were classified within the 7th and 8th AJCC/TNM classification
and the treatment modalities and survival outcomes compared.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
32
RESULTS
• The study was conducted on (222) Non-small cell lung cancer patients
between 20 and 80 years.
• All the 222 patients were classified with both the AJCC TNM 7th edition and
then reclassified with the AJCC TNM 8th edition to enable the comparison.
• There were no chances made in the nodal(N) category between the 7th and
8th AJCC/TNM staging. Majority of the patients had N3 disease.
• 7th edition, involvement of the mediastinal pleura was classified as T3 disease
it has since been removed from the T classification in TNM 8th edition
• The changes effected were, the 7th edition T1a was divided into the 8th edition
T1a and T1b categories, T2a was divided into T2a and T2b categories, T3 category
was recategorized into T2, T3 and T4 groups.
• In the Metastatic (M) category 7th edition, the division of metastatic disease
into M1a and M1b demonstrates an important change in TNM 8th Edition,
intrathoracic metastasis retains the M1a designation, but the extra thoracic
metastasis group has been split into M1b (single extra thoracic metastasis in a single
distant organ) and M1c (multiple extra thoracic metastases in one or more distant
organs)
• The comparison of the two staging systems.
33
Overall survival
Age in years
<30years 30-39 40-49 50-59 60+
Gender
Male Female
Nodal staging
N0 N1 N2 N3
Invasion
Plueral invasion Vessel invasion none
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
34
Relationship between overall survival
and age.
Relationship between overall survial and gender.
Relationship between overall survival and nodal staging.
Relationship between overall survival and plueral or vessel invasion.
Relationship between 7th Tumour stage and Overall survival.
35
Relationship between 8th Tumour stage and Overall survival.
Relationship between 7th stage and overall survival.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
36
Relationship between 8th stage and overall survival.
CONCLUSIONS
• We were able to show that the survival time decreases as the pathological stage progresses.
• There were no changes in the Nodal staging between the 7th and the 8th edition.
• The metastatic staging that was changed was also shown to have an impact on survival outcomes.
• The 8th edition was shown to be more discriminatory in showing this.
37
Phase III Concurrent chemo-radiotherapy of weekly
paclitaxel versus weekly carboplatin in locally advanced
head and neck unfit for cisplatin
Abd el motaleb Mohamed 1 , Ahmed Z. Elattar 1 , Ahmed Hassan 2 , Mona Salah 1
1-Clinical Oncology Department, Faculty of Medicine Zagazig University
2-1-Clinical Oncology Department , Faculty of Medicine Ain Shams University
INTRODUCTION
In Egypt, the head and neck cancers represented 17% of all malignant [1]. But in United
State ofAmerica the head and neck cancer about 3 to 5% of all cancers and about 90 %
was squamous cell carcinoma and the incidence of head and neck cancers in United States
was 40000 people per year [2]. Most of squamous cell carcinoma presented in locally
advanced stage and treated with chemoradiotherapy protocol [2]. Many trails and meta-
analysis confirm benefits of survival and organ preservation adding chemotherapy to
radiotherapy in different sequences especially concurrent chemo-radiotherapy
AIM:
This prospective randomized study aiming to comparing the efficacy and toxicities of
concurrent chemo radiotherapy of weekly Taxol versus weekly carboplatin in locally
advanced head and neck carcinoma unfit for cisplatin.
SACRالجمعية العلمية �بحاث السرطانلمساعدة مرضى ا�ورام بصعيد مصر
Clinical Oncology Department Assiut University
12th
38
PATIENT AND METHODS:
The patient divided in two arms, paclitaxel arm; 25patients treated by weekly paclitaxel
40mg /m2 with radiotherapy and carboplatin arm; 25 patients treated by weekly 150 mg
carboplatin with radiotherapy. The three-dimensional radiotherapy planned (3DCRT)
was 65 to 70 GY and 1.8 -2 GY /fraction, 5 fractions/week in 6-7 weeks.
RESULTS:
There was an insignificant 5-year disease free survival was 79.5% in carboplatin arm
versus 84.6% in paclitaxel arm and 5-year OS was an insignificant 76% in carboplatin
arm versus 72% in paclitaxel arm (p-value=0.646) . A 44% of both arms had overall
complete remission. A 16% of patients received carboplatin had grade III/IV mucositis.
Patients in paclitaxel arm had more grade II neuropathy (60%). A comparable rate of
neutropenia had occurred in both arms.
CONCLUSION:
Both arms of concurrent chemo radiotherapy had acceptable toxicities with good
quality of life response to treatment where 44% of both arms had complete
response (p-value=0.623). There was an insignificant 5-year disease free survival
was 79.5% in carboplatin arm versus 84.6% in paclitaxel arm and 5-year OS was
an insignificant 76% in carboplatin arm versus 72% in paclitaxel arm
(p-value=0.646) . A 44% of both arms had overall complete remission
Platinum
Golden
Silver
Others
OFFICIAL ORGANIZER: ARAB ORGANIZERS FOR CONFERENCE MANAGEMENTAddress : 14 Mohamed Mandour Rabaa El Adaweya St.,-Nasr CityTel.: 0222603653 Mobile : +20 100 222 3158 / +20 1068663434 / +20 1068666085E-mail address : [email protected] Website: www.araborganizers.org